# QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors

> **NCT06892925** · PHASE2 · RECRUITING · sponsor: **Eastern Hepatobiliary Surgery Hospital** · enrollment: 59 (estimated)

## Conditions studied

- Biliary Tract Tumors

## Interventions

- **DRUG:** QL1706

## Key facts

- **NCT ID:** NCT06892925
- **Lead sponsor:** Eastern Hepatobiliary Surgery Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-14
- **Primary completion:** 2026-04
- **Final completion:** 2029-04
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06892925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06892925, "QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06892925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*